The Phase 3 clinical trial (NCT04958265) evaluating Crovalimab for pediatric participants with atypical hemolytic uremic syndrome (aHUS) reached its primary completion on July 4, 2025. This milestone signifies the conclusion of the main data collection period for the study.

Background

Crovalimab, also known as Piasky, is an investigational drug being studied for its potential in treating atypical hemolytic uremic syndrome (aHUS). aHUS is a rare, life-threatening genetic disease characterized by chronic, uncontrolled activation of the complement system, leading to inflammation and damage to small blood vessels in the kidneys and other organs. This Phase 3 study specifically focuses on evaluating the efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab in a pediatric population.

Trial design

The study, officially titled 'A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS),' is registered under identifier NCT04958265. It is a Phase 3 trial that has enrolled 41 pediatric participants diagnosed with atypical hemolytic uremic syndrome. The trial is designed to assess the effects of crovalimab as an intervention. The overall status of the trial is currently ACTIVE_NOT_RECRUITING, indicating that participant enrollment is complete and the study is ongoing.

What this means

The primary completion of the Phase 3 trial for Crovalimab in pediatric aHUS marks a critical step in its development. While specific efficacy and safety results are not yet available, this completion means that the core data collection for the primary objectives has concluded. Researchers will now proceed with comprehensive data analysis, which will inform the potential future regulatory submissions and availability of crovalimab as a treatment option for this vulnerable patient population.

Source

Information regarding the primary completion of this trial was obtained from the ClinicalTrials.gov database, a public registry of clinical studies. The record for study NCT04958265, titled 'A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS),' was updated to reflect primary completion on July 4, 2025, and is available on clinicaltrials.gov.